ABSTRACT
The title of this chapter has implications that differ greatly according to the reader's perspective. The physician needs to know what relationship the cardiodepressant has with altered cardiac function; the pharmacologist would like to know about functional abnormalities and whether these functional abnormalities can be accounted for by known differences at molecular levels. In an attempt to be global in our exposition, we tried to address each of these concerns.
